<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31232" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vitiligo</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahmed jan</surname>
            <given-names>Naila</given-names>
          </name>
          <aff>Sandeman Provincial Hospital/BMCH Quetta</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Masood</surname>
            <given-names>Sadia</given-names>
          </name>
          <aff>Aga Khan University Hospital karachi</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold> Naila Ahmed jan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sadia Masood declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31232.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Vitiligo is a common acquired skin disorder which results from the loss of melanocytes from the epidermis and clinically manifests as well-demarcated white patches on the body. There are different theories about the pathogenesis of vitiligo but exact etiology is still unknown. It is a form of autoimmune disorder. This activity reviews the role of the interprofessional team in the diagnosis and treatment of this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of vitiligo.</p></list-item><list-item><p>Identify the clinical features of the various clinical types of vitiligo.</p></list-item><list-item><p>Explain the various treatment options available for vitiligo.</p></list-item><list-item><p>Outline the importance of collaboration and communication amongst the interprofessional team to ensure the appropriate treatment for vitiligo patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31232&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31232">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31232.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Vitiligo is an acquired pigmentary skin disorder by the absence of pigmentary cells from the epidermis that results in white macules and patches on the body.<xref ref-type="bibr" rid="article-31232.r1">[1]</xref>&#x000a0;The condition is usually associated with few autoimmune disorders, with thyroid abnormalities are the commonest one. The etiology of vitiligo is unknown but there are different theories to explain its pathogenesis. Vitiligo presents clinically with signs and symptoms of white spots on the body distributed symmetrically and more obvious in people with dark skin. The lesions are characterized by well-demarcated pearly white or depigmented macules and patches, oval, round, or linear-shaped, and the borders are convex,&#x000a0;range from the size of few millimeters to centimeters and enlarge centrifugally. There are different clinical variants of vitiligo which are Trichrome, Marginal inflammatory, and Quadrichrome vitiligo. Koebner phenomenon(Development of vitiligo at specific trauma prone sites, like cut, burn, or abrasion)is also a common clinical manifestation. Initial lesions occur most frequently on the hands, forearms, feet, and&#x000a0;face, favoring a periocular or perioral distribution.<xref ref-type="bibr" rid="article-31232.r2">[2]</xref><xref ref-type="bibr" rid="article-31232.r3">[3]</xref></p>
        <p>On the basis of the distribution, pattern Vitiligo is classified into three types, generalized, segmental, and localized. The severity of the disease is scored by the body surface area affected. The course of the disease is often unpredictable and varies in response to the treatment. Depigmentation often the cause of psychological distress, social stigmatization, and low self-esteem.<xref ref-type="bibr" rid="article-31232.r3">[3]</xref></p>
      </sec>
      <sec id="article-31232.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of vitiligo is unknown. It is frequently associated with multiple autoimmune diseases. There are various theories about its pathogenesis and the etiology is multifactorial. It is characterized by incomplete penetrance, genetic heterogeneity, and multiple susceptibility loci. Family and other twin studies have shown that inheritance is complex and also involves both environmental and genetic factors. Additionally, it is hypothesized that&#x000a0;genetic factors can influence the age of onset of vitiligo. The inheritance of vitiligo may also include genes associated with the biosynthesis of melanin, regulation of autoantibodies, and response to oxidative stress.<xref ref-type="bibr" rid="article-31232.r4">[4]</xref></p>
        <p>Recent research studies have not highlighted any associations with any certain HLA type. There is a strong reason to believe that&#x000a0;segmental and nonsegmental vitiligo have a unique genetic mechanism, which can account for variable treatment responses.<xref ref-type="bibr" rid="article-31232.r5">[5]</xref></p>
      </sec>
      <sec id="article-31232.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Vitiligo is the commonest cause of depigmentation. It can appear at any age from child to adulthood but peak incidence is reported in the second and third decade. The age of onset usually varies between the sexes. Its prevalence is approximately 0.1% to 2% of people including adults and children worldwide and it affects all races equally.<xref ref-type="bibr" rid="article-31232.r6">[6]</xref></p>
      </sec>
      <sec id="article-31232.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Vitiligo is commonly known as multifactorial polygenic disorder and has complex pathogenesis. It is commonly associated with both non-genetic and genetic factors. However various theories have been proposed about its pathogenesis but the exact etiology is still unknown. The generally agreed principles are the absence of melanocytes in vitiligo skin with melanocytes loss, owing to their destruction. The destruction is most results in progressive melanocytes decreases. Theories about the melanocyte destruction include cytotoxic mechanisms, autoimmune mechanisms, intrinsic melanocyte defects, neural mechanisms, and oxidant-antioxidant mechanisms.<xref ref-type="bibr" rid="article-31232.r5">[5]</xref></p>
        <p>In the neural hypothesis, a neurochemical mediator usually destroys the melanocytes and decreases the production of melanin. In oxidant and anti-oxidant mechanism intermediate or metabolic product of melanin synthesis causes the destruction of the melanocyte.<xref ref-type="bibr" rid="article-31232.r7">[7]</xref> In the intrinsic defect of melanocyte, there is an inherent abnormality that impedes their growth and differentiation. Another hypothesis is autoimmune or cytotoxic one where there is an alteration in humoral and cellular immunity that causes the destruction or dysfunction of melanocytes. This theory supports the hypothesis that nonsegmental vitiligo is commonly associated with autoimmune disorders than the segmental type of vitiligo.</p>
      </sec>
      <sec id="article-31232.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The basic histopathological findings in vitiligo is a total loss of functioning melanocytes in association with the complete loss of epidermal pigmentation (determined by Fontana-Masson stain or dohydrophenylalanine. Immunohistochemistry for melanocyte-specific markers like Melan-A and HMB-45 and specific electron microscopy can also be used).<xref ref-type="bibr" rid="article-31232.r1">[1]</xref></p>
        <p>In the margins of lesions, perivascular and perifollicular lymphocytic infiltrate (CD4+ and CD8+ T lymphocytes) are seen, they have specific melanocytic toxicity. Degenerative changes in melanocytes are also visible like cellular enlargement, cytoplasmic vacuolization, and long dendritic processes filled with melanin granules. Other reported changes include epidermal vacuolization, increase number of Langerhans cells, and basement membrane thickening.<xref ref-type="bibr" rid="article-31232.r8">[8]</xref></p>
      </sec>
      <sec id="article-31232.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In most cases, the diagnosis of vitiligo is very clear based on clinical findings but detailed history and examination are necessary for disease severity.<xref ref-type="bibr" rid="article-31232.r2">[2]</xref></p>
        <p>Important points of history that are helpful in the diagnosis of vitiligo include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age at onset of lesions</p>
          </list-item>
          <list-item>
            <p>Factors or events that may cause the onset of vitiligo</p>
          </list-item>
          <list-item>
            <p>Symptoms associated with the lesions</p>
          </list-item>
          <list-item>
            <p>Progression or spread of lesions</p>
          </list-item>
          <list-item>
            <p>Changes observed in lesions over time</p>
          </list-item>
          <list-item>
            <p>Presence of concomitant diseases</p>
          </list-item>
          <list-item>
            <p>Current medications</p>
          </list-item>
          <list-item>
            <p>Occupational history/exposure to chemicals or radiation</p>
          </list-item>
          <list-item>
            <p>Family history of vitiligo and autoimmune diseases&#x000a0;</p>
          </list-item>
        </list>
        <p>Physical examination of vitiligo reveals these findings:<xref ref-type="bibr" rid="article-31232.r9">[9]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Vitiligo manifest as depigmented macules or patches with a convex border without signs of inflammation with normal skin around.</p>
          </list-item>
          <list-item>
            <p>Macules are milky-white in color, well-demarcated with either round, oval, or linear in shape.</p>
          </list-item>
          <list-item>
            <p>Ranges in size from a few millimeters to a few centimeters.</p>
          </list-item>
          <list-item>
            <p>Common sites are face, neck, dorsum of hands, scalp, and trunk. On the face, lesion favors perioral and periocular distribution.</p>
          </list-item>
          <list-item>
            <p>Lesions can also occur in areas that are subjected to trauma like knees and elbows.</p>
          </list-item>
          <list-item>
            <p>Koebnerization may occur in 20% to 60% of vitiligo patients.</p>
          </list-item>
          <list-item>
            <p>Signs of other associated diseases may also be present like Goiter, anemia, generalized wasting, premature grey hairs (leukonychia), alopecia areata and weakness,&#x000a0;etc.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31232.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of vitiligo is usually made on clinical features, through a wood light examination biopsy is sometimes helpful to differentiate vitiligo from other hypopigmented or depigmented disorders.<xref ref-type="bibr" rid="article-31232.r10">[10]</xref> The histopathological examination of the skin reveals the absence of melanocytes and complete epidermal pigmentation loss. Superficial perifollicular and&#x000a0;perivascular lymphocytic infiltrates may be present at the margin of the vitiligo lesions, due to the cell-mediated process that destroys the melanocytes.<xref ref-type="bibr" rid="article-31232.r11">[11]</xref></p>
        <p>Other reported histological findings are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Degenerative changes of both melanocytes and keratinocytes located at the border and also of adjacent skin</p>
          </list-item>
          <list-item>
            <p>Langerhans cells are increased in numbers.</p>
          </list-item>
          <list-item>
            <p>Vacuolization of epidermis</p>
          </list-item>
          <list-item>
            <p>Basement membrane thickening</p>
          </list-item>
          <list-item>
            <p>Pigmentary loss and epidermal melanocytes stained with Fontana-Masson staining and immunohistochemistry testing.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31232.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Various types of topical and systemic medications, phototherapy, laser therapy, and surgical therapy are used for the treatment of vitiligo. Topical treatment, modalities include corticosteroids, calcineurin inhibitors, and&#x000a0;vitamin-D analogs. Phototherapy is an effective treatment option. It induces repigmentation in most of the patients with early and localizes the disease. Narrowband UV-B is widely used, mostly two to three times in a week with 311-312nm wavelength. It has largely replaced the psoralen photochemotherapy because of its toxic side effects.&#x000a0;Excimer Laser is used to treating limited, stable patches of vitiligo. In segmental vitiligo which is resistant to most of the treatments, Tacrolimus and systemic corticosteroids can be combined with it.<xref ref-type="bibr" rid="article-31232.r12">[12]</xref>&#x000a0;Afamelanotide and JAK inhibitor therapy are emerging treatments. Topical ruxolitinib was also found to be very effective(in 2019 randomized placebo-controlled, double-blind prospective trial)</p>
        <p>Surgical treatment options are limited to segmental or localize vitiligo that is limited to a small area. Five basic methods of repigmentation include non cultured epidermal suspensions, thin dermo-epidermal grafts, suction epidermal graft, punch grafting, and cultured epidermis with melanocytes.<xref ref-type="bibr" rid="article-31232.r13">[13]</xref>&#x000a0;The following patients are good candidates for surgical treatment.</p>
        <list list-type="bullet">
          <list-item>
            <p>Segmental vitiligo</p>
          </list-item>
          <list-item>
            <p>Localize vitiligo involving small area</p>
          </list-item>
          <list-item>
            <p>Vitiligo in areas which usually not re-pigment well (hairline, dorsal fingers, forehead, ankles)</p>
          </list-item>
          <list-item>
            <p>The lesion must be stable.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31232.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p><bold>Nevus depigmentosus:</bold>&#x000a0;It is a circumscribed, segmental depigmented or hypopigmented area present at birth.</p>
          </list-item>
          <list-item>
            <p><bold>Pityriasis alba:</bold>&#x000a0;It commonly considered as a spectrum of atopic dermatitis and usually affect the children. It presents as white hypopigmented, scaly macules and patches on the face and other photo exposed areas.</p>
          </list-item>
          <list-item>
            <p><bold>Idiopathic guttate hypomelanosis: </bold>It is characterized by small, asymptomatic pearly white macules on photo exposed areas. Most of these lesions appear in older age groups.</p>
          </list-item>
          <list-item>
            <p><bold>Tinea (pityriasis) Versicolor:</bold> It is a superficial fungal infection that causes loss of pigment. It appears as pale scaly macules present on the back and chest. They give yellow fluorescence under Wood's lamp [</p>
          </list-item>
          <list-item>
            <p><bold>Halo nevus</bold>: It is a type of melanocytic nevus surrounded by an oval halo of depigmentation</p>
          </list-item>
          <list-item>
            <p><bold>Progressive macular hypomelanosis:&#x000a0;</bold>It is clinically present as asymptomatic hypopigmented patches on the trunk of young adults</p>
          </list-item>
          <list-item>
            <p><bold>Drug-induced leukoderma:</bold> Potent topical or intralesional corticosteroids can induce hypopigmentation at the site of application. Depigmentation is also noticed in patients treated with the tyrosine kinase and epidermal growth factor receptor inhibitor.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Hypopigmented mycosis fungoides: </bold>It is a variant of early-stage MF commonly seen in children and dark-skinned people. It appears as widespread hypopigmented patches with atrophy and scaling and atrophy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31232.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Psoralen photochemotherapy; adverse effects include phototoxic effect, nausea, and risk of skin cancer. Short-term adverse effects of NB-UVB include itching, burning, and xerosis.</p>
      </sec>
      <sec id="article-31232.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>It is a chronic skin condition with an unpredictable disease course and some patients may notice spontaneous repigmentation over the depigmented areas.<xref ref-type="bibr" rid="article-31232.r14">[14]</xref>&#x000a0;The prognosis depends upon the age of onset and the extent of disease. Early disease onset is usually associated with the involvement of greater body surface area and rate of progression. Few types and certain locations may be responsive to treatment. Refractory cases have been noted in patients presenting with segmental vitiligo and younger than 14 years of age. Most of the patients on treatment usually experience intermittent cycles of pigment loss and disease stabilization.<xref ref-type="bibr" rid="article-31232.r7">[7]</xref></p>
      </sec>
      <sec id="article-31232.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of vitiligo are social stigmatization and mental stress, eye involvement like iritis, depigmented skin is more prone to sunburn, skin cancer, and hearing loss because of loss of cochlear melanocytes. Other complications are related to medications like skin atrophy after prolonged use of topical steroids.</p>
      </sec>
      <sec id="article-31232.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>An interprofessional approach is very essential for such patients. Sometimes these patients need special referrals to respective specialties when present with another autoimmune disorder. In addition, for ocular complications consultation with an ophthalmologist and psychological ailments referral to mental health, specialists are important.</p>
      </sec>
      <sec id="article-31232.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>As vitiligo is a depigmented and slowly progressive disorder it affects the physical appearance of a patient, and because of this, it has a psychological and social impact. Visible lesions have been associated with more distress and stigmatization than non-visible lesions, lower quality of life is reported in patients with vitiligo. Psychiatric consultation is very important because of psychiatric morbidity. Patient education regarding the slow response of treatment or treatment failure is also necessary because the response to treatment is highly variable in different patients.</p>
      </sec>
      <sec id="article-31232.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A multidisciplinary approach is important because vitiligo is associated with other autoimmune disorders. A proper collaboration and communication are very important. These patients present with multiple psychological disorders due to their appearance and unpredictable course. Psychological interventions are important. Cognitive-behavioral therapy, along with regular conventional treatment is very useful in improving the self-esteem confidence and quality of life of such patients, and it also influences the disease course.</p>
      </sec>
      <sec id="article-31232.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31232&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31232">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/vitiligo/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31232">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31232/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31232">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-31232.s18">
        <fig id="article-31232.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Vitiligo, Hand <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="vitiligo" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-31232.s19">
        <fig id="article-31232.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Woods light for vitiligo patient showed depigmented patch. Contributed by Daifallah Al Aboud, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG_3314" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-31232.s20">
        <fig id="article-31232.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Figure 1. New vitiligo macules over the forehead of a recently married Indian lady, which appeared within 3 weeks of application of vermillion paste (maroon-colored) over the mid portion of the frontal scalp line. Contributed by Sidharth Sonthalia, MD, DNB, MNAMS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Question__Pic__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-31232.s21">
        <fig id="article-31232.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Vitiligo. Genitals Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Vitiligo__SV1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-31232.s22">
        <fig id="article-31232.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Vitiligo, Facial Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Vitiligo__SV1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-31232.s23">
        <title>References</title>
        <ref id="article-31232.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzei Weiss</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Vitiligo: to biopsy or not to biopsy?</article-title>
            <source>Cutis</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>105</volume>
            <issue>4</issue>
            <fpage>189</fpage>
            <page-range>189-190</page-range>
            <pub-id pub-id-type="pmid">32463851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eleftheriadou</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Reliability and validity of the Vitiligo Signs of Activity Score.</article-title>
            <source>Br J Dermatol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>183</volume>
            <issue>5</issue>
            <fpage>801</fpage>
            <page-range>801-802</page-range>
            <pub-id pub-id-type="pmid">32458411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Baat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Phoa</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Zweers</surname>
                <given-names>PGMA</given-names>
              </name>
              <name>
                <surname>Bolling</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rozema</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Vissink</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide].</article-title>
            <source>Ned Tijdschr Tandheelkd</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>237</fpage>
            <page-range>237-243</page-range>
            <pub-id pub-id-type="pmid">32459219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel-Malek</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Upadhyay</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Fleischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamzavi</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The enigma and challenges of vitiligo pathophysiology and treatment.</article-title>
            <source>Pigment Cell Melanoma Res</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>778</fpage>
            <page-range>778-787</page-range>
            <pub-id pub-id-type="pmid">32198977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henning</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Jaishankar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barse</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Dellacecca</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Lancki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Janusek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Le Poole</surname>
                <given-names>IC</given-names>
              </name>
            </person-group>
            <article-title>The relationship between stress and vitiligo: Evaluating perceived stress and electronic medical record data.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>e0227909</fpage>
            <pub-id pub-id-type="pmid">31986193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ezzedine</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Vitiligo: A Review.</article-title>
            <source>Dermatology</source>
            <year>2020</year>
            <volume>236</volume>
            <issue>6</issue>
            <fpage>571</fpage>
            <page-range>571-592</page-range>
            <pub-id pub-id-type="pmid">32155629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Manga</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Elbuluk</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>669</fpage>
            <page-range>669-680</page-range>
            <pub-id pub-id-type="pmid">32468356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lei</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Hearing</surname>
                <given-names>VJ</given-names>
              </name>
            </person-group>
            <article-title>Deciphering skin re-pigmentation patterns in vitiligo: an update on the cellular and molecular events involved.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2020</year>
            <month>May</month>
            <day>20</day>
            <volume>133</volume>
            <issue>10</issue>
            <fpage>1231</fpage>
            <page-range>1231-1238</page-range>
            <pub-id pub-id-type="pmid">32433056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gr&#x000e4;n</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Emmerich</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mohme</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goebeler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gesierich</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.</article-title>
            <source>Eur J Dermatol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-73</page-range>
            <pub-id pub-id-type="pmid">32250264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Husseiny</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abd-Elhaleem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salah El-Din</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Abdallah</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Childhood vitiligo in Egypt: Clinico-epidemiologic Profile of 483 patients.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>237</fpage>
            <page-range>237-242</page-range>
            <pub-id pub-id-type="pmid">32320520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delgadillo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Systemic and Autoimmune Diseases.</article-title>
            <source>Clin Colon Rectal Surg</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>372</fpage>
            <page-range>372-376</page-range>
            <pub-id pub-id-type="pmid">31507347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juntongjin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Toncharoenphong</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of a combined 308-nm excimer lamp and topical mid-potent steroid treatment for facial vitiligo: a preliminary, randomized double-blinded controlled study.</article-title>
            <source>Lasers Med Sci</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>2023</fpage>
            <page-range>2023-2029</page-range>
            <pub-id pub-id-type="pmid">32458080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ju</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Eun</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Skin seeding technique with 0.5-mm micropunch grafting for vitiligo irrespective of the epidermal-dermal orientation: Animal and clinical studies.</article-title>
            <source>J Dermatol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>7</issue>
            <fpage>749</fpage>
            <page-range>749-754</page-range>
            <pub-id pub-id-type="pmid">32452060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31232.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Cancer risks in patients with vitiligo: a Mendelian randomization study.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>146</volume>
            <issue>8</issue>
            <fpage>1933</fpage>
            <page-range>1933-1940</page-range>
            <pub-id pub-id-type="pmid">32462299</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
